TDMS No. 95003 - 06	P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)	Date Report Requested: 10/09/2009
Test Type: CHRONIC	Methyl trans-styryl ketone	Time Report Requested: 14:36:21
Route: SKIN APPLICATION	CAS Number: 1896-62-4	First Dose M/F: 04/26/04 / 04/26/04
Species/Strain: MICE/B6C3F1		Lab: SRI
	F1_M3	
C Number:	C05003C	

C95003C
01/29/2007
ALL
ALL
ALL
ALL
Include ALL
Both
2.1.0

# Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

#### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
isposition Summary					
Animals Initially in Study	50	50	50	50	
Early Deaths					
Accidently Killed		1			
Moribund Sacrifice	4	2	8	5	
Natural Death	12	12	7	7	
Survivors					
Terminal Sacrifice	34	35	35	38	
Animals Examined Microscopically	50	50	50	50	
LIMENTARY SYSTEM					
Gallbladder	(40)	(38)	(44)	(38)	
Inflammation, Acute				1 (3%)	
Intestine Large, Cecum	(41)	(46)	(46)	(46)	
Intestine Large, Colon	(39)	(43)	(44)	(43)	
Edema			1 (2%)		
Intestine Large, Rectum	(41)	(43)	(46)	(46)	
Inflammation, Acute		1 (2%)			
Intestine Small, Duodenum	(40)	(42)	(44)	(43)	
Hemorrhage				1 (2%)	
Intestine Small, Ileum	(40)	(44)	(45)	(43)	
Inflammation, Acute			1 (2%)		
Inflammation, Chronic				1 (2%)	
Intestine Small, Jejunum	(41)	(42)	(45)	(44)	
Inflammation, Acute	1 (2%)		1 (2%)		
Inflammation, Chronic				1 (2%)	
Mineralization		1 (2%)			
Necrosis	1 (2%)	1 (2%)	1 (2%)		
Liver	(50)	(50)	(50)	(49)	
Angiectasis	2 (4%)		1 (2%)		
Basophilic Focus	5 (10%)	5 (10%)	3 (6%)	3 (6%)	
Basophilic Focus, Multiple				1 (2%)	
Bile Stasis		2 (4%)	1 (2%)		
Clear Cell Focus	17 (34%)	18 (36%)	15 (30%)	18 (37%)	
Congestion	1 (2%)	2 (4%)	· ·		
Cyst				2 (4%)	
Eosinophilic Focus	17 (34%)	14 (28%)	16 (32%)	13 (27%)	
Fatty Change	1 (2%)				
Hematopoietic Cell Proliferation	4 (8%)	1 (2%)	4 (8%)	7 (14%)	
Hemorrhage	2 (4%)	2 (4%)	· ·		
Hyperplasia, Lymphoid	1 (2%)	. ,			

# Test Type: CHRONIC

**Route: SKIN APPLICATION** 

Species/Strain: MICE/B6C3F1

#### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

#### CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Inflammation, Acute	1 (2%)				
Inflammation, Chronic		2 (4%)			
Mixed Cell Focus	2 (4%)	5 (10%)	2 (4%)	4 (8%)	
Necrosis, Focal	15 (30%)	7 (14%)	8 (16%)	6 (12%)	
Thrombosis			1 (2%)	1 (2%)	
Centrilobular, Necrosis	1 (2%)				
Hepatocyte, Hypertrophy		1 (2%)		1 (2%)	
Hepatocyte, Vacuolization Cytoplasmic	1 (2%)	2 (4%)	1 (2%)		
Mesentery	(6)	(12)	(8)	(6)	
Fibrosis		1 (8%)	1 (13%)	1 (17%)	
Hemorrhage		3 (25%)	( , ,	1 (17%)	
Inflammation, Chronic				1 (17%)	
Artery, Hyperplasia				1 (17%)	
Fat, Necrosis	5 (83%)	5 (42%)	7 (88%)	4 (67%)	
Pancreas	(49)	(50)	(50)	(49)	
Angiectasis	1 (2%)	(00)	(00)	(10)	
Inflammation, Chronic	1 (270)	1 (2%)			
Lipomatosis		1 (2%)	1 (2%)		
Metaplasia, Hepatocyte	1 (2%)	1 (270)	1 (270)		
Salivary Glands	(50)	(50)	(50)	(50)	
Atrophy	1 (2%)	(56)	2 (4%)	(30)	
Hyperplasia, Lymphoid	12 (24%)	13 (26%)	11 (22%)	10 (20%)	
Inflammation, Chronic Active	12 (2478)	1 (2%)	11 (2270)	10 (20%)	
Mineralization	1 (2%)	2 (4%)	1 (2%)		
Necrosis	1 (278)	1 (2%)	1 (278)		
Stomach, Forestomach	(50)	(50)	(50)	(50)	
Cyst	(50)	(50)	(30)	1 (2%)	
Edema		1 (2%)	1 (2%)	1 (270)	
Erosion	4 (8%)	1 (278)	2 (4%)		
Inflammation, Chronic	4 (078)	3 (6%)	3 (6%)	3 (6%)	
Ulcer	2 (4%)	2 (4%)	5 (10%)	1 (2%)	
Epithelium, Hyperplasia	5 (10%)	7 (14%)	7 (14%)	6 (12%)	
Stomach, Glandular	(47)	(49)	(49)	(48)	
Cyst	2 (4%)	1 (2%)	13 (27%)	5 (10%)	
Erosion	2 (4%)	1 (2%)	3 (6%)	1 (2%)	
Hemorrhage	2 (476)	1 (278)	3 (078)	1 (2%)	
	1 (20/)		E (109()	1 (2%)	
Inflammation, Acute Inflammation, Chronic	1 (2%)		5 (10%)	2 (4%)	
Metaplasia, Squamous	1 (29/)	2 (4%)	1 (29()		
Mineralization	1 (2%)		1 (2%)	1 (2%)	
		3 (6%)	2 (4%)		
Necrosis	1 (20/)	2(40/)	1 (2%)		
Ulcer	1 (2%)	2 (4%)			
Epithelium, Hyperplasia	2 (4%)	1 (2%)		(0)	
Tooth	(1)	(1)	(0)	(0)	
Malformation	1 (100%)	1 (100%)			

# Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

# P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
CARDIOVASCULAR SYSTEM					
Heart Cardiomyopathy Mineralization Thrombosis Artery, Inflammation, Chronic	(50) 11 (22%)	(50) 7 (14%) 1 (2%)	(50) 8 (16%) 2 (4%)	(50) 4 (8%) 1 (2%) 1 (2%)	
ENDOCRINE SYSTEM					
Adrenal Cortex Accessory Adrenal Cortical Nodule Degeneration, Fatty Hyperplasia	(50) 2 (4%) 4 (8%) 2 (4%)	(50) 1 (2%) 12 (24%)	(50) 2 (4%) 9 (18%)	(49) 8 (16%) 6 (12%)	
Hyperplasia, Focal Hypertrophy, Focal Capsule, Hyperplasia Adrenal Medulla Hyperplasia Islets, Pancreatic	1 (2%) 16 (32%) 38 (76%) (49) 4 (8%) (50)	1 (2%) 16 (32%) 40 (80%) (50) 2 (4%) (50)	1 (2%) 20 (40%) 40 (80%) (50) 1 (2%) (50)	12 (24%) 36 (73%) (49) 5 (10%) (49)	
Angiectasis Hyperplasia Parathyroid Gland Cyst Pituitary Gland Pars Distalis, Cyst Pars Distalis, Hyperplasia, Focal	1 (2%) 28 (56%) (48) 2 (4%) (49) 4 (8%)	23 (46%) (47) 1 (2%) (49) 4 (8%) 1 (2%)	28 (56%) (48) 1 (2%) (50) 5 (10%) 1 (2%)	19 (39%) (45) 3 (6%) 2 (4%)	
Pars Intermedia, Cyst Thyroid Gland Cyst	(50) 1 (2%)	(49)	1 (2%) 1 (2%) (50)	(49)	
Follicle, Degeneration, Focal Follicular Cell, Hyperplasia, Focal		1 (2%)	1 (2%)	2 (4%) 1 (2%)	
GENERAL BODY SYSTEM					
Tissue NOS Fibrosis	(2) 1 (50%)	(2)	(2)	(0)	
GENITAL SYSTEM					
Epididymis	(50)	(50)	(50)	(50)	

# Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

#### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Amyloid Deposition, Chronic Angiectasis		4 (29())	1 (2%)	1 (2%)	
Fibrosis Granuloma Sperm		1 (2%)	2 (4%)		
Hemorrhage Inflammation, Chronic	1 (2%)	1 (2%) 3 (6%)		3 (6%)	
Necrosis Spermatocele	1 (2%)	1 (2%)		1 (2%)	
Penis Congestion Inflammation, Acute	(0)	(0)	(2) 1 (50%) 1 (50%)	(0)	
Preputial Gland Atrophy	(50) 1 (2%)	(50)	(50)	(50)	
Cyst Hyperplasia	3 (6%)	3 (6%)	7 (14%) 1 (2%)	5 (10%)	
Hyperplasia, Squamous Inflammation, Chronic Inflammation, Chronic Active Prostate Angiectasis	1 (2%) 13 (26%) 1 (2%) (50)	18 (36%) 3 (6%) (50) 1 (2%)	12 (24%) 4 (8%) (50)	15 (30%) 6 (12%) (48) 1 (2%)	
Cyst Inflammation, Chronic Necrosis	1 (2%) 1 (2%)	8 (16%)	6 (12%)	2 (4%) 6 (13%)	
Polyarteritis Epithelium, Hyperplasia Seminal Vesicle Fibrosis Infiltration Cellular	27 (54%) (50) 1 (2%)	20 (40%) (50) 1 (2%)	16 (32%) (50)	2 (4%) 25 (52%) (49) 1 (2%) 2 (4%)	
Infiltration Cellular, Lymphocyte Inflammation, Chronic Epithelium, Hyperplasia	2 (4%) 1 (2%)	4 (8%)		1 (2%) 1 (2%)	
Testes Angiectasis Germinal Epithelium, Atrophy Interstitial Cell, Hyperplasia	(50) 6 (12%)	(50) 3 (6%)	(50) 1 (2%) 1 (2%) 1 (2%)	(50) 1 (2%) 1 (2%)	
HEMATOPOIETIC SYSTEM					
Bone Marrow Hyperplasia Infiltration Cellular, Histiocyte	(50)	(50)	(50)	(50) 1 (2%) 1 (2%)	
Myelofibrosis Thrombosis Lymph Node Hemorrhage	(5) 1 (20%)	(5)	1 (2%) (4)	1 (2%) (6)	

# Test Type: CHRONIC

#### Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

#### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

### CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Pigmentation	1 (20%)				
Iliac, Hemorrhage			1 (25%)	1 (17%)	
lliac, Hyperplasia, Lymphoid	2 (40%)		1 (25%)		
Inguinal, Hyperplasia				1 (17%)	
Inguinal, Hyperplasia, Lymphoid	1 (20%)	( (		1 (17%)	
Mediastinal, Hyperplasia, Lymphoid	1 (000())	1 (20%)			
Renal, Hyperplasia, Lymphoid	1 (20%)	(40)	(50)	(40)	
Lymph Node, Mandibular	(49)	(46)	(50)	(49)	
Atrophy Hematopoietic Cell Proliferation	3 (6%)			1 (2%) 1 (2%)	
Hemorrhage	1 (2%)	1 (2%)		1 (270)	
Hyperplasia, Lymphoid	2 (4%)	1 (2%)		6 (12%)	
Hyperplasia, Plasma Cell	2 (470)	1 (2%)		1 (2%)	
Lymph Node, Mesenteric	(49)	(44)	(49)	(45)	
Atrophy	9 (18%)	4 (9%)	4 (8%)	8 (18%)	
Fibrosis	1 (2%)	1 (0,70)	1 (0,73)	1 (2%)	
Hematopoietic Cell Proliferation	3 (6%)		2 (4%)		
Hemorrhage	3 (6%)	3 (7%)	2 (4%)	2 (4%)	
Hyperplasia, Histiocytic	1 (2%)			1 (2%)	
Hyperplasia, Lymphoid	4 (8%)	2 (5%)	2 (4%)	6 (13%)	
Hyperplasia, Plasma Cell	2 (4%)	2 (5%)	2 (4%)	4 (9%)	
Infiltration Cellular, Neutrophil	2 (4%)	1 (2%)	2 (4%)	3 (7%)	
Inflammation, Chronic	1 (2%)			1 (2%)	
Spleen	(48)	(47)	(49)	(49)	
Fibrosis	11 (000())		1 (2%)	00 (440()	
Hematopoietic Cell Proliferation	11 (23%)	16 (34%)	16 (33%)	20 (41%)	
Necrosis		1 (20()		1 (2%)	
Pigmentation Lymphoid Follicle, Atrophy	1 (29/)	1 (2%) 4 (9%)	2 (4%)	2(49/)	
Lymphoid Follicle, Hyperplasia	1 (2%)	4 (9%) 1 (2%)	2 (4%) 2 (4%)	2 (4%) 3 (6%)	
Thymus	(44)	(48)	(46)	(40)	
Cyst	10 (23%)	7 (15%)	4 (9%)	4 (10%)	
INTEGUMENTARY SYSTEM					
Mammary Gland	(50)	(50)	(50)	(50)	
Infiltration Cellular				1 (2%)	
Skin	(50)	(50)	(50)	(50)	
Cyst Epithelial Inclusion		1 (2%)	1 (2%)		
Edema		2 (4%)	1 (2%)	- (()	
Hyperkeratosis	1 (2%)	3 (6%)	1 (2%)	5 (10%)	
Hyperplasia, Melanocyte		1 (2%)	0 ( 40 ( )	C (400()	
Inflammation, Chronic		3 (6%)	2 (4%)	6 (12%)	
Metaplasia, Osseous Ulcer		1 (2%) 1 (2%)	1 (2%)		
UICEI		I (∠/0)	1 (2/0)		

# Test Type: CHRONIC

#### Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

#### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

# CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Epidermis, Hyperplasia Epidermis, Site Of Application, Hyperplasia Prepuce, Hyperkeratosis Site Of Application, Erosion	7 (14%)	2 (4%) 13 (26%) 1 (2%)	29 (58%) 1 (2%)	4 (8%) 37 (74%)	
Site Of Application, Fibrosis Site Of Application, Hyperkeratosis Site Of Application, Hyperplasia, Melanocyte	17 (34%)	1 (2%) 19 (38%) 1 (2%)	5 (10%) 26 (52%) 23 (46%)	1 (2%) 40 (80%) 44 (88%)	
Site Of Application, Inflammation, Chronic Site Of Application, Ulcer Site Of Application, Subcutaneous Tissue,	1 (2%)	8 (16%) 2 (4%)	15 (30%) 2 (4%)	43 (86%) 5 (10%) 1 (2%)	
Hemorrhage Subcutaneous Tissue, Hemorrhage				1 (2%)	
/USCULOSKELETAL SYSTEM					
Bone Osteopetrosis	(50)	(49)	(50) 1 (2%) 2 (4%)	(50)	
Cranium, Osteopetrosis Skeletal Muscle	2 (4%) (1)	1 (2%) (4)	2 (4%) (1)	(1)	
NERVOUS SYSTEM					
Brain Compression	(50)	(50)	(50)	(50) 1 (2%)	
Congestion Hemorrhage Hyperplasia, Lymphoid Infiltration Cellular, Histiocyte, Focal	1 (2%) 2 (4%)	5 (10%) 2 (4%)	4 (8%)	1 (2%) 5 (10%) 1 (2%) 1 (2%)	
RESPIRATORY SYSTEM					
Lung Congestion Hemorrhage	(50) 2 (4%) 2 (4%)	(50) 3 (6%) 6 (12%)	(50) 1 (2%) 2 (4%)	(50)	
Hyperplasia, Lymphoid Infiltration Cellular, Histiocyte Inflammation, Suppurative	1 (2%) 8 (16%) 1 (2%)	3 (6%)	8 (16%)	2 (4%) 12 (24%)	
Inflammation, Chronic Metaplasia, Osseous Necrosis	1 (2%) 1 (2%)		1 (2%) 1 (2%)		
Thrombosis Alveolar Epithelium, Hyperplasia Nose	5 (10%) (50)	1 (2%) 6 (12%) (50)	5 (10%) (50)	8 (16%) (50)	

# Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Foreign Body	1 (2%)			3 (6%)	
Inflammation, Suppurative Inflammation, Chronic	1 (2%) 6 (12%)	6 (12%)	5 (10%)	2 (4%) 3 (6%)	
Inflammation, Chronic Active Respiratory Epithelium, Hyperplasia	0 ((12)0)	0 (1270)	2 (4%)	2 (4%) 1 (2%)	
Respiratory Epithelium, Metaplasia,			1 (2%)	1 (270)	
Squamous Trachea	(50)	(50)	(50)	(50)	
Inflammation, Chronic			1 (2%)		
SPECIAL SENSES SYSTEM					
Eye	(49) 1 (2%)	(48)	(48)	(45) 1 (2%)	
Atrophy Fibrosis				1 (2%)	
Inflammation, Chronic Inflammation, Chronic Active	1 (2%)	1 (2%)	1 (2%)	1 (2%) 4 (9%)	
Cornea, Hyperplasia Cornea, Necrosis		1 (2%)	1 (2%)	4 (9%) 1 (2%)	
Retina, Vacuolization Cytoplasmic	(10)	(= 0)	1 (2%)		
Harderian Gland Fibrosis	(48) 1 (2%)	(50)	(50)	(50)	
Hyperplasia Hyperplasia, Focal	2 (4%)	1 (2%) 2 (4%)	1 (2%)	3 (6%)	
Inflammation, Chronic	3 (6%)	3 (6%)	1 (270)	2 (4%)	
Metaplasia, Osseous				1 (2%)	
JRINARY SYSTEM					
Kidney Casts Granular	(48)	(49) 2 (4%)	(49)	(47)	
Casts Protein		1 (2%)			
Cyst Hyperplasia, Lymphoid	15 (31%) 10 (21%)	13 (27%) 18 (37%)	7 (14%) 10 (20%)	9 (19%) 18 (38%)	
Hyperplasia, Oncocytic	1 (2%)		10 (2070)		
Infarct Inflammation, Suppurative	2 (4%)	4 (8%) 1 (2%)		2 (4%)	
Inflammation, Chronic	1 (2%)		4 (00/)	2 (0)()	
Metaplasia, Osseous Nephropathy	6 (13%) 41 (85%)	8 (16%) 43 (88%)	4 (8%) 45 (92%)	3 (6%) 45 (96%)	
Capsule, Fibrosis Capsule, Pigmentation	. ,		· ·	1 (2%) 1 (2%)	
Papilla, Necrosis	1 (2%)	3 (6%)		. ,	
Pelvis, Dilatation	1 (2%)	1 (2%)		1 (2%)	

# Test Type: CHRONIC

#### Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

#### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

#### CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Renal Tubule, Accumulation, Hyaline Droplet				1 (2%)	
Renal Tubule, Dilatation, Focal		1 (2%)		1 (2%)	
Renal Tubule, Hyperplasia	2 (4%)	2 (4%)	2 (4%)	. ,	
Renal Tubule, Necrosis	. ,		1 (2%)	1 (2%)	
Renal Tubule, Pigmentation		1 (2%)		1 (2%)	
Urethra	(1)	(0)	(0)	(0)	
Bulbourethral Gland, Necrosis	1 (100%)				
Urinary Bladder	(49)	(48)	(49)	(48)	
Edema		3 (6%)			
Hemorrhage	1 (2%)				
Hyperplasia, Lymphoid	1 (2%)	2 (4%)	1 (2%)	1 (2%)	
Necrosis	1 (2%)	1 (2%)	. ,		

\*\*\* END OF MALE \*\*\*

# Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Disposition Summary					
Animals Initially in Study	50	50	50	50	
Early Deaths	50	50	50	50	
Moribund Sacrifice	6	6	10	7	
Natural Death	7	5	9	6	
Survivors Terminal Sacrifice	37	39	31	37	
Animals Examined Microscopically	50	59 50	50	50	
·					
ALIMENTARY SYSTEM					
Gallbladder	(44)	(47)	(40)	(43)	
Intestine Large, Cecum	(47)	(49)	(45)	(46)	
Edema		(47)	1 (2%)		
Intestine Large, Colon	(44)	(47) 1 (2%)	(42)	(44)	
Edema Inflammation, Acute		1 (2%) 1 (2%)	2 (5%)		
Intestine Large, Rectum	(45)	(48)	(43)	(44)	
Intestine Small, Duodenum	(43)	(47)	(43)	(44)	
Hyperplasia	()	1 (2%)	( )		
Ulcer		1 (2%)			
Intestine Small, Ileum	(43)	(45)	(42)	(45)	
Dilatation		0 ( 10)	1 (2%)		
Inflammation, Acute		2 (4%)	1 (2%)		
Epithelium, Hyperplasia Intestine Small, Jejunum	(43)	(46)	1 (2%) (42)	(44)	
Necrosis	(43)	(40)	(42) 1 (2%)	(44)	
Liver	(50)	(50)	(50)	(49)	
Angiectasis	3 (6%)	3 (6%)	(30)	(	
Basophilic Focus	4 (8%)	2 (4%)	3 (6%)	2 (4%)	
Bile Stasis		1 (2%)	1 (2%)		
Clear Cell Focus	6 (12%)	3 (6%)	5 (10%)	4 (8%)	
Congestion	16 (229/)	1 (2%)	14 (200/)	15 (219/)	
Eosinophilic Focus Fatty Change	16 (32%) 1 (2%)	13 (26%)	14 (28%)	15 (31%)	
Hematopoietic Cell Proliferation	13 (26%)	15 (30%)	6 (12%)	8 (16%)	
Hemorrhage	2 (4%)	1 (2%)	1 (2%)	0 (10,0)	
Hyperplasia, Lymphoid	2 (4%)	5 (10%)	1 (2%)	6 (12%)	
Infarct		1 (2%)	1 (2%)	. ,	
Inflammation, Chronic	1 (2%)				
Karyomegaly Mixed Call Facus	4 (00()	0 (40/)	1 (2%)		
Mixed Cell Focus	1 (2%)	2 (4%)	2 (4%)		

# Test Type: CHRONIC

#### Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

#### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

#### CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

Necrosis, Focal					
	6 (12%)	10 (20%)	10 (20%)	5 (10%)	
Vacuolization Cytoplasmic		2 (4%)			
Centrilobular, Necrosis	1 (2%)	1 (2%)			
Hepatocyte, Hypertrophy			5 (10%)		
Hepatocyte, Vacuolization Cytoplasmic	1 (2%)	2 (4%)		1 (2%)	
Kupffer Cell, Pigmentation	2 (4%)	2 (4%)	2 (4%)		
Mesentery	(16)	(22)	(17)	(13)	
Congestion	1 (6%)				
Fibrosis	1 (6%)				
Hemorrhage		1 (5%)		1 (8%)	
Fat, Necrosis	15 (94%)	21 (95%)	17 (100%)	11 (85%)	
Pancreas	(50)	(50)	(49)	(47)	
Atrophy	2 (4%)	4 (8%)	1 (2%)	3 (6%)	
Cyst		2 (4%)	2 (4%)	3 (6%)	
Fibrosis		. ,	1 (2%)		
Hyperplasia, Lymphoid	1 (2%)		2 (4%)	1 (2%)	
Inflammation, Granulomatous, Chronic Active	<b>X Y</b>		1 (2%)		
Inflammation, Focal, Chronic		1 (2%)	( ),		
Metaplasia, Hepatocyte		( ),	1 (2%)		
Mineralization			1 (2%)		
Necrosis		1 (2%)			
Acinus, Hyperplasia, Focal	1 (2%)	( ),		1 (2%)	
Salivary Glands	(50)	(50)	(50)	(50)	
Atrophy	1 (2%)	(	1 (2%)	( ),	
Hyperplasia, Lymphoid	20 (40%)	14 (28%)	12 (24%)	23 (46%)	
Mineralization	3 (6%)	1 (2%)	( ),	( )	
Stomach, Forestomach	(50)	(50)	(50)	(50)	
Edema	()	1 (2%)	1 (2%)	()	
Erosion	2 (4%)	1 (2%)	( ),		
Inflammation, Chronic	1 (2%)	1 (2%)	2 (4%)		
Ulcer	2 (4%)	2 (4%)	4 (8%)	5 (10%)	
Epithelium, Hyperplasia	6 (12%)	7 (14%)	10 (20%)	4 (8%)	
Stomach, Glandular	(48)	(48)	(48)	(46)	
Cyst	5 (10%)	3 (6%)	8 (17%)	4 (9%)	
Edema	(		1 (2%)	( )	
Erosion		3 (6%)	1 (2%)	1 (2%)	
Foreign Body		· · · · /		1 (2%)	
Inflammation, Acute				1 (2%)	
Mineralization	1 (2%)	1 (2%)	1 (2%)	2 (4%)	
Ulcer	1 (2%)		1 (2%)	( · · · /	
Epithelium, Hyperplasia	1 (2%)		1 (2%)		
RDIOVASCULAR SYSTEM					
Heart	(50)	(50)	(50)	(50)	

# Test Type: CHRONIC

Species/Strain: MICE/B6C3F1

Route: SKIN APPLICATION

# P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a) Methyl trans-styryl ketone

CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Cardiomyopathy Mineralization	8 (16%) 1 (2%)	12 (24%) 1 (2%)	10 (20%) 3 (6%)	9 (18%)	
NDOCRINE SYSTEM					
Adrenal Cortex	(50)	(49)	(50)	(50)	
Accessory Adrenal Cortical Nodule	6 (12%)	2 (4%)	4 (8%)	1 (2%)	
Degeneration, Fatty	3 (6%)	2 (4%)	1 (2%)	1 (2%)	
Hematopoietic Cell Proliferation	2 (4%)	(	2 (4%)	2 (4%)	
Hyperplasia, Focal	1 (2%)	2 (4%)	1 (2%)		
Hypertrophy, Focal		2 (4%)	1 (2%)	4 (8%)	
Capsule, Hyperplasia	48 (96%)	47 (96%)	49 (98%)	50 (100%)	
Adrenal Medulla	(50)	(49)	(50)	(50)	
Hyperplasia	2 (4%)	4 (8%)	2 (4%)	3 (6%)	
Islets, Pancreatic	(50)	(50)	(49)	(47)	
Angiectasis	()	()	()	1 (2%)	
Hyperplasia	4 (8%)	2 (4%)	4 (8%)	5 (11%)	
Parathyroid Gland	(46)	(48)	(46)	(46)	
Inflammation, Chronic	(10)	(10)	(10)	1 (2%)	
Pituitary Gland	(47)	(49)	(50)	(46)	
Pars Distalis, Angiectasis	()	2 (4%)	2 (4%)	1 (2%)	
Pars Distalis, Cyst	1 (2%)	= (1,0)	3 (6%)	1 (2%)	
Pars Distalis, Hyperplasia	3 (6%)	1 (2%)	0 (070)	. (=/3)	
Pars Distalis, Hyperplasia, Focal	6 (13%)	6 (12%)	12 (24%)	5 (11%)	
Pars Intermedia, Cyst	1 (2%)	0 (1270)	12 (2470)	0 (11/0)	
Pars Intermedia, Hyperplasia, Focal	1 (2%)		1 (2%)		
Pars Intermedia, Hypertrophy	1 (270)		1 (270)	1 (2%)	
Thyroid Gland	(49)	(50)	(49)	(47)	
Infiltration Cellular, Lymphocyte	1 (2%)	(00)	(40)	(1)	
Inflammation, Acute	· (~/0)			1 (2%)	
Inflammation, Chronic		1 (2%)	1 (2%)	1 (270)	
Ultimobranchial Cyst		1 (270)	· (∠ /0)	1 (2%)	
Bilateral, Follicular Cell, Hyperplasia, Diffuse		1 (2%)		I (∠/0)	
Follicle, Degeneration, Focal	30 (61%)	31 (62%)	35 (71%)	31 (66%)	
Follicular Cell, Hyperplasia		1 (2%)	1 (2%)	2 (4%)	
Follicular Cell, Hyperplasia, Focal	2 (4%)	2 (4%)	2 (4%)	2 (7/0)	
ENERAL BODY SYSTEM	2 (770)	2 (470)	2 (770)		
Tissue NOS	(3)	(2)	(4)	(0)	
Fibrosis	(3) 1 (33%)	(2)	(4)	(0)	
Abdominal, Fat, Inflammation, Chronic Active	1 (33%)		1 (25%)		
Appointmal, Fat, initiattimation, Unionic Active			I (ZJ70)		

# Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

#### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
GENITAL SYSTEM					
Clitoral Gland	(48)	(49)	(50)	(46)	
Inflammation, Chronic	2 (4%)	1 (2%)	(10)	1 (2%)	
Ovary	(49)	(50)	(48)	(50)	
Angiectasis Cyst	1 (2%) 9 (18%)	1 (2%) 17 (34%)	6 (13%)	1 (2%) 10 (20%)	
Hemorrhage	9 (18%) 9 (18%)	15 (30%)	17 (35%)	18 (36%)	
Inflammation, Chronic	9 (10%)	13 (30 %)	1 (2%)	10 (30 %)	
Mineralization			1 (2%)		
Thrombosis	1 (2%)	2 (4%)	5 (10%)	3 (6%)	
Interstitial Cell, Hyperplasia	3 (6%)		1 (2%)	- ()	
Uterus	(50)	(50)	(49)	(50)	
Angiectasis	1 (2%)	1 (2%)			
Hemorrhage	1 (2%)		1 (2%)	1 (2%)	
Hyperplasia, Cystic	49 (98%)	46 (92%)	43 (88%)	47 (94%)	
Hyperplasia, Histiocytic Metaplasia, Osseous				1 (2%) 1 (2%)	
Pigmentation		1 (2%)		1 (2%)	
Myometrium, Hypertrophy		1 (278)	1 (2%)		
Vagina	(1)	(2)	(1)	(0)	
Hyperplasia, Squamous	(')	1 (50%)		(-)	
Inflammation, Chronic		1 (50%)			
Necrosis		1 (50%)			
IEMATOPOIETIC SYSTEM					
Bone Marrow	(50)	(50)	(50)	(50)	
Angiectasis			1 (2%)	1 (2%)	
Hyperplasia, Megakaryocyte			1 (22())	1 (2%)	
Infiltration Cellular, Histiocyte Myelofibrosis	1 (20()		1 (2%)	1 (20()	
Myeloid Cell, Hyperplasia	1 (2%)		1 (2%)	1 (2%) 1 (2%)	
Lymph Node	(13)	(11)	(15)	(14)	
Ectasia	2 (15%)	3 (27%)	6 (40%)	3 (21%)	
Fibrosis	_ ( ,	- ( /-)	- (	1 (7%)	
Hematopoietic Cell Proliferation		1 (9%)			
Hemorrhage	1 (8%)	3 (27%)	4 (27%)	2 (14%)	
Hyperplasia, Lymphoid				1 (7%)	
Bronchial, Hyperplasia, Lymphoid		1 (9%)	a (1001)		
lliac, Ectasia	2 (15%)		2 (13%)	1 (7%)	
Iliac, Hemorrhage	1 (8%)		1 (7%) 1 (7%)	1 (7%) 1 (7%)	
Iliac, Hyperplasia, Lymphoid					

#### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

Methyl trans-styryl ketone **CAS Number:** 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Renal, Ectasia			1 (7%)		
Renal, Hyperplasia, Lymphoid Renal, Infiltration Cellular, Histiocyte	1 (8%)		1 (7%) 1 (7%)		
Lymph Node, Mandibular	(50)	(48)	(46)	(50)	
Atrophy	2 (4%)	1 (2%)	(40)	4 (8%)	
Ectasia	2 (173)	(2)0)		1 (2%)	
Hemorrhage		2 (4%)		. (=,-,)	
Hyperplasia, Histiocytic		(	1 (2%)		
Hyperplasia, Lymphoid	11 (22%)	7 (15%)	4 (9%)	2 (4%)	
Lymph Node, Mesenteric	(47)	(49)	(45)	(48)	
Atrophy	5 (11%)	3 (6%)	2 (4%)	6 (13%)	
Ectasia			1 (2%)		
Hematopoietic Cell Proliferation		2 (4%)	1 (2%)		
Hemorrhage				1 (2%)	
Hyperplasia, Lymphoid	1 (2%)	1 (2%)			
Hyperplasia, Plasma Cell	1 (2%)	1 (2%)			
Infiltration Cellular, Neutrophil	1 (2%)	1 (2%)	(10)		
Spleen	(49)	(50)	(48)	(48)	
Angiectasis	1 (2%)		24 (059()	20 (5 49()	
Hematopoietic Cell Proliferation	27 (55%)	28 (56%)	31 (65%) 1 (2%)	26 (54%) 1 (2%)	
Hyperplasia, Lymphoid Pigmentation	8 (16%)	5 (10%)	9 (19%)	3 (6%)	
Lymphoid Follicle, Atrophy	1 (2%)	5 (10%)	1 (2%)	2 (4%)	
Lymphoid Follicle, Hyperplasia	26 (53%)	20 (40%)	19 (40%)	23 (48%)	
Thymus	(50)	(46)	(46)	(48)	
Cyst	2 (4%)	1 (2%)	4 (9%)	4 (8%)	
Hemorrhage	6 (12%)	7 (15%)	10 (22%)	9 (19%)	
Hyperplasia, Lymphoid	1 (2%)	. (,)		1 (2%)	
EGUMENTARY SYSTEM					
Mammary Gland	(50)	(50)	(50)	(50)	
Hyperplasia	4 (8%)	3 (6%)	4 (8%)	4 (8%)	
Infiltration Cellular, Lymphocyte		1 (2%)			
Inflammation, Chronic		1 (2%)			
Pigmentation	()	()	<i>(</i> )	1 (2%)	
Skin	(50)	(50)	(50)	(50)	
Edema	1 (2%)	3 (6%)	2 (4%)	1 (2%)	
Hemorrhage	1 (2%)	1 (2%)	0 (00()	40 (049()	
Hyperkeratosis	3 (6%)	4 (8%)	3 (6%)	12 (24%)	
Hyperplasia, Melanocyte	1 (2%)	2(40/)	2 (4%)	3 (6%)	
Inflammation, Acute Inflammation, Chronic	1 (29/)	2 (4%)	7 (1 49/)	19 (269/)	
Inflammation, Chronic Active	1 (2%) 1 (2%)	4 (8%)	7 (14%)	18 (36%)	

# Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

#### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

# CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Epidermis, Hyperplasia Epidermis, Site Of Application, Hyperplasia Site Of Application, Erosion Site Of Application, Hemorrhage	2 (4%) 7 (14%) 1 (2%)	2 (4%) 11 (22%) 1 (2%)	2 (4%) 31 (62%) 1 (2%)	9 (18%) 33 (66%) 1 (2%)	
Site Of Application, Hyperkeratosis Site Of Application, Hyperplasia	9 (18%)	16 (32%)	37 (74%)	36 (72%) 1 (2%)	
Site Of Application, Hyperplasia, Melanocyte Site Of Application, Inflammation, Acute Site Of Application, Inflammation, Chronic	3 (6%) 7 (14%)	3 (6%) 1 (2%) 11 (22%)	33 (66%) 33 (66%)	36 (72%) 38 (76%)	
Site Of Application, Ulcer Site Of Application, Subcutaneous Tissue, Metaplasia, Osseous			2 (4%)	4 (8%) 1 (2%)	
Subcutaneous Tissue, Hemorrhage Subcutaneous Tissue, Necrosis			1 (2%) 1 (2%)		
MUSCULOSKELETAL SYSTEM					
Bone Cranium, Fibrosis Cranium, Osteopetrosis Femur, Fibro-Osseous Lesion Femur, Hyperostosis	(49) 2 (4%) 12 (24%)	(50) 1 (2%) 1 (2%) 7 (14%) 5 (10%)	(50) 1 (2%) 12 (24%) 1 (2%)	(50) 1 (2%) 2 (4%) 10 (20%) 6 (12%)	
Vertebra, Arthrosis Skeletal Muscle Degeneration Inflammation, Chronic	(3) 1 (33%)	(2) 1 (50%)	(2)	1 (2%) (3)	
NERVOUS SYSTEM					
Brain Compression Gliosis	(50)	(50) 3 (6%)	(50) 2 (4%)	(50) 3 (6%) 1 (2%)	
Hemorrhage Hyperplasia, Lymphoid Infiltration Cellular, Lipocyte Inflammation, Acute	4 (8%) 3 (6%)	2 (4%) 2 (4%)	2 (4%) 2 (4%) 1 (2%) 1 (2%)	2 (4%) 3 (6%)	
Inflammation, Chronic Metaplasia, Osseous Necrosis, Focal			1 (2%)	1 (2%) 1 (2%) 2 (4%)	
Meninges, Inflammation, Chronic Peripheral Nerve Degeneration Inflammation, Chronic	1 (2%) (1) 1 (100%) 1 (100%)	(1)	(0)	(0)	

# Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

#### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Methyl trans-styryl ketone

CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
RESPIRATORY SYSTEM					
Lung	(50)	(50)	(49)	(50)	
Congestion Fibrosis	1 (2%)	1 (2%)	1 (2%)	2 (4%) 1 (2%)	
Hemorrhage	2 (4%)	6 (12%)	3 (6%)	1 (2%)	
Hyperplasia, Lymphoid	2 (470)	0 (12,0)	0 (070)	2 (4%)	
Infiltration Cellular, Histiocyte	5 (10%)	3 (6%)	3 (6%)	4 (8%)	
Metaplasia, Osseous		1 (2%)			
Mineralization	1 (2%)				
Thrombosis	1 (2%)	8 (16%)	3 (6%)	6 (109/)	
Alveolar Epithelium, Hyperplasia Nose	5 (10%) (50)	8 (16%) (50)	3 (6%) (50)	6 (12%) (50)	
Foreign Body	(50)	(30)	1 (2%)	(50)	
Hemorrhage		1 (2%)	. (= /0)		
Inflammation, Chronic	1 (2%)	2 (4%)	2 (4%)		
Glands, Cyst		1 (2%)			
Pleura	(1)	(0)	(0)	(1)	
Eye Developmental Malformation Inflammation, Chronic Bilateral, Hemorrhage Bilateral, Retinal Detachment	(47)	(50) 2 (4%) 1 (2%) 1 (2%)	(48) 1 (2%)	(47) 1 (2%) 1 (2%)	
Bilateral, Optic Nerve, Necrosis Cornea, Hyperplasia Cornea, Inflammation, Chronic Retina, Degeneration		1 (2%) 2 (4%) 2 (4%)	3 (6%) 1 (2%)	1 (2%)	
Harderian Gland	(50)	(50)	(49)	(49)	
Cyst Fibrosis			1 (2%)	1 (2%)	
Hyperplasia	1 (2%)	- (( 22()	= (( 22()		
Hyperplasia, Focal Inflammation, Chronic Bilateral, Hemorrhage	2 (4%) 8 (16%)	5 (10%) 1 (2%) 1 (2%)	5 (10%) 3 (6%)	3 (6%)	
URINARY SYSTEM					
Kidney Casts Protein	(49)	(50)	(48) 1 (2%)	(47)	

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: MICE/B6C3F1

Methyl trans-styryl ketone

CAS Number: 1896-62-4

Date Report Requested: 10/09/2009 Time Report Requested: 14:36:21 First Dose M/F: 04/26/04 / 04/26/04 Lab: SRI

36C3F1 MICE FEMALE	0 MG/KG	10 MG/KG	30 MG/KG	90 MG/KG	
Cyst	2 (4%)	1 (2%)		3 (6%)	
Hemorrhage		( ),		1 (2%)	
Hyperplasia, Lymphoid	15 (31%)	14 (28%)	16 (33%)	11 (23%)	
Infarct	1 (2%)	7 (14%)	6 (13%)	3 (6%)	
Infiltration Cellular, Lipocyte	1 (2%)	, , , , , , , , , , , , , , , , , , ,			
Metaplasia, Osseous	2 (4%)	3 (6%)	3 (6%)	2 (4%)	
Mineralization	8 (16%)	1 (2%)	2 (4%)	2 (4%)	
Nephropathy	31 (63%)	37 (74%)	36 (75%)	30 (64%)	
Papilla, Necrosis		. ,	1 (2%)		
Pelvis, Dilatation	1 (2%)				
Renal Tubule, Accumulation, Hyaline Droplet	1 (2%)	3 (6%)	2 (4%)		
Renal Tubule, Dilatation, Focal		. ,	1 (2%)		
Renal Tubule, Necrosis		1 (2%)			
Urinary Bladder	(49)	(50)	(48)	(48)	
Hyperplasia, Lymphoid	11 (22%)	6 (12%)	10 (21%)	8 (17%)	
Inflammation, Chronic			1 (2%)		
Transitional Epithelium, Hyperplasia			1 (2%)		

\*\*\* END OF REPORT \*\*\*